Its business lead clinical-stage program.

Celator Pharmaceuticals presents data on CPX-351 Liposome Injection and HDPN formulation Celator Pharmaceuticals today announced data from animal studies demonstrating the better bone marrow uptake of CPX-351 Liposome Injection, its business lead clinical-stage program, along with the enhanced circulation kinetics and efficacy of its preclinical hydrophobic docetaxel prodrug nanoparticle formulation were presented at the 101st Annual Conference of the American Association for Malignancy Study in Washington, DC . In the first presentation, researchers reported on the circulation features and anti-tumor activity of HDPN in mice bearing HT-29 human colorectal tumor xenografts bowel disease .

Related StoriesUsing the butterfly effect to predict heart disease: an interview with Dr George and Dr Parthimos, Cardiff UniversityExercise and chronic exhaustion syndrome: an interview with Professor Trudie ChalderProtein sensor for proprioception foundThey investigated neuronal activity in the basal ganglia of a dystonia mouse model, which was produced by transferring human dystonia genes, in awake state. Basal ganglia send out inhibitory indicators to the engine cortex and tune optimal movement in normal state. Nevertheless, in the dystonia mouse model, the neuronal activity is usually decreased in order that basal ganglia cannot inhibit engine cortical activity linked to unnecessary movements.